Skip to main content

Table 3 Proteasome inhibitor related cardiac adverse events

From: Cardiac events during treatment with proteasome inhibitor therapy for multiple myeloma

Cardiac adverse event, n Bortezomib (n = 44) Carfilzomib (n = 52) Total (n = 96)
Any typea 7 14 21
Heart failure 6 7 13
 Grade 3 or 4 3 4 7
Systemic hypertension 1 3 4
 Grade 3 or 4 1 3 4
Thromboembolism 1 2 3
 Grade 3 or 4 0 0 0
Acute coronary syndrome 1 1 2
 Grade 3 or 4 1 0 1
Atrial fibrillation/flutter 0 2 2
 Grade 3 or 4 0 1 1
Pulmonary hypertension 0 1 1
 Grade 3 or 4 0 1 1
Orthostatic hypotension 0 0 0
Sudden cardiac death 0 0 0
  1. aSome patients had multiple events